Abbott's Stock Falls on Surging 53% Volume as Study Highlights Underserved HIV-Diabetes Market

. 8, , . A study published in *JAPhA Practice Innovations* highlighted significant gaps in diabetes care adherence among patients with both HIV and diabetes, raising concerns for healthcare providers and manufacturers like Abbott, whose diabetes management products could face increased demand in this underserved population.

, . The findings underscore systemic challenges in managing comorbid chronic conditions, potentially driving demand for and diagnostic tools, areas where Abbott has a strong market presence.

While the study did not directly reference Abbott, the company’s role in diabetes care—including glucose monitoring systems and insulin delivery devices—positions it to benefit from heightened focus on improving screening and management protocols for high-risk populations. However, the mixed adherence rates suggest long-term growth may depend on broader healthcare infrastructure improvements rather than product innovation alone.

To carry out this back-test rigorously, implementation details such as universe definition, volume metrics, and portfolio construction assumptions need confirmation. . stocks, . , pending approval of the outlined parameters.